Company news

PMGC Holdings Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q

August 13, 2025

PMGC Holdings Inc. Terminates LOI to Focus on Acquiring High-Growth CNC Precision Manufacturing Companies Serving Aerospace, Defense, and Industrial Markets

July 30, 2025

PMGC Holdings Inc. Completes Acquisition of CNC Machining Company - AGA Precision Systems LLC

July 18, 2025

Pacific Sun Packaging, a Subsidiary of PMGC Holdings, Announces Attendance at 2025 ITAD Summit to Showcase Custom Protective Packaging for Enterprise IT Hardware

July 17, 2025

PMGC Holdings Inc. Completes Acquisition of Custom IT Packaging Company Pacific Sun Packaging with Over $2,000,000 in Combined Revenue for Fiscal Years 2023 and 2024

July 10, 2025

PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue

June 24, 2025

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

June 18, 2025

Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases

June 17, 2025

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001: 2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years

June 16, 2025

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company

June 9, 2025

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

May 22, 2025

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

May 13, 2025

RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

April 29, 2025

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company

April 15, 2025

PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K

March 27, 2025

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

March 26, 2025

PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

March 20, 2025

Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

March 9, 2025

PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

March 5, 2025

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

February 26, 2025

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

February 25, 2025

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-...

February 17, 2025

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

January 30, 2025

PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors

January 26, 2025

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

January 23, 2025

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture

January 15, 2025

PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries

January 14, 2025

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products

January 1, 2025

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada

December 19, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

December 8, 2024

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

December 5, 2024

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

December 3, 2024

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

November 21, 2024

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

November 21, 2024

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

November 13, 2024

CORRECTION - Elevai Labs Inc.

November 13, 2024

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

November 3, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

October 21, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

October 20, 2024

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

October 3, 2024

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

October 2, 2024

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

October 1, 2024

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

September 22, 2024

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

September 9, 2024

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

September 2, 2024

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

August 27, 2024

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

August 25, 2024

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

August 18, 2024

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

← Newer news releases · Older news releases →

Decks